ProShare Advisors LLC Has $1.02 Million Stock Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

ProShare Advisors LLC lifted its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 54.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,722 shares of the company's stock after buying an additional 4,459 shares during the period. ProShare Advisors LLC's holdings in PROCEPT BioRobotics were worth $1,024,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of PRCT. FMR LLC boosted its stake in shares of PROCEPT BioRobotics by 11.9% during the 4th quarter. FMR LLC now owns 8,159,208 shares of the company's stock worth $656,979,000 after buying an additional 866,328 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of PROCEPT BioRobotics by 38.8% during the 4th quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock worth $120,051,000 after buying an additional 416,819 shares during the last quarter. Vanguard Group Inc. lifted its stake in PROCEPT BioRobotics by 6.1% in the 4th quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock valued at $413,907,000 after purchasing an additional 297,075 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in PROCEPT BioRobotics in the 4th quarter valued at about $22,422,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in PROCEPT BioRobotics by 218.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 401,210 shares of the company's stock valued at $33,350,000 after purchasing an additional 275,071 shares during the last quarter. 89.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at PROCEPT BioRobotics

In other news, CEO Reza Zadno sold 5,475 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the transaction, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at approximately $9,875,374.20. This trade represents a 3.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $41,824.98. Following the transaction, the chief financial officer now directly owns 107,991 shares in the company, valued at $6,161,966.46. This represents a 0.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,455 shares of company stock valued at $368,322. 17.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on PRCT shares. Morgan Stanley cut their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Bank of America cut their target price on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating for the company in a research note on Friday, April 25th. Finally, Truist Financial cut their target price on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, April 11th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, PROCEPT BioRobotics currently has a consensus rating of "Moderate Buy" and a consensus price target of $90.00.

PROCEPT BioRobotics Stock Up 1.9%

PROCEPT BioRobotics stock opened at $57.72 on Friday. The stock has a market cap of $3.19 billion, a P/E ratio of -29.60 and a beta of 1.10. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a twelve month low of $47.04 and a twelve month high of $103.81. The company's 50-day moving average price is $55.27 and its two-hundred day moving average price is $71.08.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.04. The firm had revenue of $69.16 million for the quarter, compared to analysts' expectations of $65.39 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business's revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.51) EPS. As a group, analysts expect that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.